Verus Capital Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Verus Capital Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$15K	Buy	+494	New	+$16.5K	﹤0.01%	880

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFA

Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

CPA

Capital Planning Advisors Roseville, California $692M AUM 21.81% 1-Year Est. Return

Verus Capital Partners's ARKG Position: Q1 2020 in Review

Verus Capital Partners opened a new position in ARK Genomic Revolution ETF (ARKG) in Q1 2020: 494 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #880 among its holdings.

106 funds tracked by Wall St. Rank hold ARKG as of Q1 2020.

Verus Capital Partners held 494 shares of ARK Genomic Revolution ETF worth $15K as of Q1 2020.
ARK Genomic Revolution ETF was a new Verus Capital Partners position in Q1 2020.
ARK Genomic Revolution ETF made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #880 holding.
106 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.